Last reviewed · How we verify
Investigator's Choice Treatment
Investigator's Choice Treatment is a Small molecule drug developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd. It is currently in Phase 2 development.
At a glance
| Generic name | Investigator's Choice Treatment |
|---|---|
| Sponsor | Shanghai Runshi Pharmaceutical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (PHASE3)
- Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigator's Choice Treatment CI brief — competitive landscape report
- Investigator's Choice Treatment updates RSS · CI watch RSS
- Shanghai Runshi Pharmaceutical Technology Co., Ltd portfolio CI
Frequently asked questions about Investigator's Choice Treatment
What is Investigator's Choice Treatment?
Investigator's Choice Treatment is a Small molecule drug developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd.
Who makes Investigator's Choice Treatment?
Investigator's Choice Treatment is developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd (see full Shanghai Runshi Pharmaceutical Technology Co., Ltd pipeline at /company/shanghai-runshi-pharmaceutical-technology-co-ltd).
What development phase is Investigator's Choice Treatment in?
Investigator's Choice Treatment is in Phase 2.